GlaxoSmithKline plc’s (GSK - Free Report) HIV subsidiary, ViiV Healthcare, received Priority Review designation from the FDA for the new drug application for its long-acting, injectable two-drug HIV regimen
Glaxo had filed the NDA in April seeking approval for the two-drug monthly regimen of its candidate cabotegravir and J&J’s (JNJ - Free Report) Edurant (rilpivirine) for the treatment of HIV-1-infected adults who had maintained viral suppression and who are not resistant to cabotegravir or rilpivirine.With the FDA granting a Priority Review in June, a decision is expected on Dec 29, 2019.
Meanwhile, ViiV Healthcare also announced the start of the first-ever study — CUSTOMIZE — to identify and evaluate approaches to implementing its once-monthly injectable HIV treatment in the real world. This approach can be different and an improvement from the controlled setting of a clinical study
ViiV Healthcare is an HIV company majorly owned by Glaxo and Pfizer (PFE - Free Report) .
So far this year, Glaxo’s shares have outperformed the industry, rising 6% compared with the industry’s 2.6% increase.
HIV is a key therapeutic area for Glaxo with successful dolutegravir-based regimens, Tivicay, Triumeqand Juluca in its portfolio. In April, ViiV Healthcare gained FDA approval for a single-tablet two-drug regimen, Dovato for treatment naïve HIV- 1 adults. HIV sales totaled £1.12 billion in the first quarter of 2019 with dolutegravir-based regimens generating £1.07 million, which partly offset lower sales of established HIV products. However, on the call, the company specified that growth in the dolutegravir franchise was slower than past quarters due to a more competitive environment.
ViiV Healthcare is focused on advancing HIV care by exploring new treatment paradigms (two-drug regimens), new modalities (long-acting injectables) and new mechanisms of actions (including maturation inhibitors and broadly neutralizing antibodies). Other than the long-acting, injectable two-drug regimen of cabotegravir and rilpivirine, Glaxo has fostemsavir in its HIV pipeline, which has been developed to treat heavily pre-treated HIV patients. An NDA for fostemsavir is expectedto be filedin second-half 2019.
Other key players in the HIV market are Gilead (GILD - Free Report) , Merck, AbbVie and J&J.
Glaxo currently carries a Zacks Rank #3 (Hold). You can see the complete list of today’s Zacks #1 Rank (Strong Buy) stocks here.
More Stock News: This Is Bigger than the iPhone!
It could become the mother of all technological revolutions. Apple sold a mere 1 billion iPhones in 10 years but a new breakthrough is expected to generate more than 27 billion devices in just 3 years, creating a $1.7 trillion market.
Zacks has just released a Special Report that spotlights this fast-emerging phenomenon and 6 tickers for taking advantage of it. If you don't buy now, you may kick yourself in 2020.
Click here for the 6 trades >>